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Abstract
Heterozygous mutations in the PHOX2B gene are causative of congenital central hypoventilation
syndrome (CCHS), a neurocristopathy characterized by defective autonomic control of breathing
due to the impaired differentiation of neural crest cells. Among PHOX2B mutations, polyalanine
(polyAla) expansions are almost exclusively associated with isolated CCHS, whereas frameshift
variants, although less frequent, are often more severe than polyAla expansions and identified in
syndromicCCHS. This article provides a complete reviewof all the frameshiftmutations identified
in cases of isolated and syndromic CCHS reported in the literature as well as those identified by
us and not yet published. These were considered in terms of both their structure, whether the
underlying indels induced frameshifts of either 1 or 2 steps (“frame 2” and “frame 3” mutations
respectively), and clinical associations. Furthermore, we evaluated the structural and functional
effects of one “frame 3” mutation identified in a patient with isolated CCHS, and one “frame 2”
mutation identified in a patient with syndromic CCHS, also affected with Hirschsprung's disease
andneuroblastoma. Thedata thusobtained confirm that the typeof translational frameaffects the
severity of the transcriptional dysfunction and the predisposition to isolated or syndromic CCHS.
K EYWORDS
congenital central hypoventilation syndrome, dominant-negative, frameshift mutations, gain-of-
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1 INTRODUCTION
The paired-like homeobox 2B (PHOX2B) gene encodes a key home-
obox transcription factor that is involved in the development of
the autonomic nervous system (ANS) and the neuronal structures
controlling breathing (Pattyn, Morin, Cremer, Goridis, & Brunet,
1999; Pattyn, Hirsch, Goridis, & Brunet, 2000). It is the disease-
defining gene of congenital central hypoventilation syndrome (CCHS;
MIM# 209880), a very rare neonatal neurocristopathy caused by
the defective migration and/or differentiation of neural crest deriva-
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
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tives. CCHS is characterized by an abnormal ventilatory response
to hypoxia and hypercapnia due to a failure of autonomic respira-
tory control that leads to hypoventilation during sleep (in less severe
forms) and during both sleep and while awake in the most severe
cases.
CCHSmay be isolated or associated with other neurocristopathies,
including tumors originating from the sympathetic nervous system
(TSNS) such as neuroblastomas (NBs; MIM# 613013), ganglioneu-
romas and ganglioneuroblastomas (GNBs), autonomic dysfunctions
of the enteric nervous system such as the aganglionic megacolon
HumanMutation. 2018;39:219–236. wileyonlinelibrary.com/journal/humu 219
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Hirschsprung's disease (HSCR, the association of CCHS and HSCR is
known as “Haddad syndrome”; MIM# 209880) and/or milder intesti-
nal phenotypes (gastroesophageal reflux, constipation), and symp-
toms that can be attributed to the defective differentiation of the
neural crest cells (cardiac arrhythmias, ocular, and endocrinological
disorders) (Amiel et al., 2003; Matera et al., 2004; Weese-Mayer
et al., 2010). Such complex phenotypes are due to the many genes
expressed in different districts of the ANS that have been identified
as PHOX2B transcriptional targets, including dopamine beta hydrox-
ylase (DBH), paired-like homeobox 2A (PHOX2A), REarranged during
Transfection (RET), T-Cell Leukemia Homeobox 2 (TLX-2), and PHOX2B
itself (Adachi, Browne, & Lewis, 2000; Bachetti, Borghini, Ravazzolo,
& Ceccherini, 2005a; Borghini et al., 2006; Cargnin, Flora, Di Lascio,
Battaglioli, Longhi, Clementi, & Fornasari, 2005; Flora, Lucchetti, Ben-
fante, Goridis, Clementi, & Fornasari, 2001).
PHOX2B is a protein of 314 amino acids that is highly conserved in
mammals and has two short and stable polyalanine (polyAla) repeats
of nine and 20 residues in the C-terminus. Over 90% of patients with
CCHS are heterozygous for in-frame triplet duplications within the
sequence stretch coding for 20 alanine amino acids, and the conse-
quent polyAla repeat expansion mutations (PARMs) produce 4–13
additional alanine residues; the remaining 10% have heterozygous
non-PARM mutations (NPARMs) in exon 1, 2, or 3 that include mis-
sense (MS), nonsense (NS), and frameshift (FS) mutations, the last of
which lead to an aberrant C-terminal region (Amiel et al., 2003; Ami-
moto, Okada, Nakano, Sasaki, Hayasaka, & Odajima, 2014; Bachetti
& Ceccherini, 2013; Berry-Kravis, Zhou, Rand, &Weese-Mayer, 2006;
Buchan, Minneci, Nugent, Bryson, & Jones, 2013; Holzinger et al.,
2005; Matera et al., 2004; Raabe et al., 2008; Rand, Carroll, & Weese-
Mayer, 2014; Sasaki et al., 2003; Szymońska et al., 2015; Trochet et al.,
2005b, 2008;Weese-Mayer et al., 2003, 2010, 2017).
Previous studies have revealed the following genotype–phenotype
correlations: (1) the longer the stretch of alanine, the worse the res-
piratory phenotype; and (2) PARMs are almost exclusively identi-
fied in isolated CCHS, whereas NPARMs are often associated with
syndromic forms in which the disease occurs together with HSCR
and/or a NB, or other less frequent ANS disorders. However, NPARMs
may have widely variable phenotypic expressivity, with the majority
causing very severe forms of syndromic CCHS, and a small subset
causing milder phenotypes with reduced penetrance that may rep-
resent isolated CCHS, isolated HSCR and/or NB (Berry-Kravis et al.,
2006; Matera et al., 2004; McConville, Reid, Baskcomb, Douglas, &
Rahman, 2006; Mosse, Laudenslager, Khazi, Carlisle, Winter, Rappa-
port, & Maris, 2004; Rand, Carroll, & Weese-Mayer, 2014; Trochet
et al., 2005b, 2008; van Limpt et al., 2004). One further genotype–
phenotype correlation in the case of NPARMs suggests that transla-
tion frame 2 (resulting from the insertion of triplets +1 nucleotide or
the deletion of triplets+2 nucleotides) may predispose to a severe and
fully penetrant phenotype, whereas frame 3 (resulting from the inser-
tion of triplets+2 nucleotides or the deletion of triplets+1 nucleotide)
may contribute to a less severe and incompletely penetrant pheno-
type (Weese-Mayer et al., 2010). In line with this, in vitro studies
have shown that the transactivation of the DBH and TLX-2 promot-
ers is drastically impaired when PHOX2B carries frame 2 FS muta-
tions, but only partially compromised in the presence ofPHOX2B frame
3 mutants (Bachetti, Matera, Borghini, Di Duca, Ravazzolo, & Cec-
cherini, 2005b; Borghini et al., 2006; Trochet et al., 2005a, 2009). How-
ever, despite these observations, the molecular mechanisms underly-
ing a predisposition to the development of severe associated diseases
such as HSCR andNB in NPARM-carrying CCHS patients need further
investigation.
In an attempt to elucidate the degree of associationwith other neu-
rocristopathies, we classified reported and still unreported NPARMs
on the basis of their different translational frames. Furthermore, we
analyzed the consequences of two FS mutations (one frame 2 and one
frame 3) by predicting protein structural changes and characterizing
their functional effects in terms of promoter transactivation of the
genes involved in ANS development and, probably, the pathogenesis
of HSCR and NBs. The obtained data confirm that the type of transla-
tional frame affects the severity of the transcriptional dysfunction and
the predisposition to isolated or syndromic CCHS, thus reinforcing the
correlation with the disease phenotype.
2 MATERIALS AND METHODS
2.1 Patient samples
From 2004 to date, samples of 305 patients with symptoms sug-
gestive of hypoventilation have been recruited at the Gaslini Hos-
pital to undergo PHOX2B testing. CCHS-related PHOX2B mutations
were identified by sequencing in 116 (38%) cases. The remaining 189
patients with no detectable PHOX2Bmutation are clinically heteroge-
neous, with twenty of them who received a different clinical diagnosis
afterward.
The parental DNA of CCHS patients with identified PHOX2Bmuta-
tions was screened by direct DNA sequencing in 102 families (96 pairs
of parents and 6 single parents).
2.2 Mutational screening of the PHOX2B gene
All three exons of the PHOX2B coding region were analyzed using
published protocols (Bachetti et al., 2005b; Matera et al., 2004), in
which their amplification was followed by product purification and
direct Sanger sequencing.Mosaicismwas analyzed bymodifying a pre-
viously reported protocol: the region spanning the polyAla stretchwas
amplified using a 6′FAM-conjugated oligonucleotide and AccuPrime
GC-Rich DNA Polymerase (Thermo Fisher Scientific, Waltham, MA,
USA) and the PCR product was run using the capillary electrophoresis
method (see Bachetti, Parodi, Di Duca, Santamaria, Ravazzolo, & Cec-
cherini, 2011 for details).
GenBank sequence NG_008243.1 was used as reference for the
PHOX2BgenewhileNM_003924.3andNP_003915.2wereusedas ref-
erence sequences for PHOX2B cDNA and protein respectively.
The PHOX2B variants identified in our cohort of patients
have been submitted to the locus-specific database (LSDB) at
https://www.lovd.nl/PHOX2B.
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2.3 Cell cultures, transient transfections, and
Luciferase assays
The HeLa cells were grown in Dulbecco's modified Eagle's medium
(Lonza, Basel, Switzerland) and the SK-N-BE and U251-MG cells were
grown in RPMI (Euroclone, Pero, Milan, Italy), with the addition of
10% fetal calf serum, penicillin 100 units/ml, streptomycin 100 𝜇g/ml,
and L-glutamine (Gln) 2 mM (Sigma–Aldrich, St. Louis, MO, USA).
The transfection and co-transfection experiments were performed
by means of lipofection as previously described (Di Lascio, Belperio,
Benfante, & Fornasari, 2016) using 5 × 104 cells. The luciferase assays
were carried out using the Dual Luciferase Reporter Assay System as
previously described (Bachetti et al., 2005b). All of the transfections
were performed in triplicate, and each construct was tested in at least
three independent experiments using different batches of plasmid
preparation.
2.4 Generation of the expression and reporter
constructs
In expression plasmids, the full name of mutant proteins derived
from c.618del (p.Ser207Alafs*102) and c.930dup (p.Ser311Glufs*49)
cDNAs has been shortened in p.Ser207fs and p.Ser311fs, respectively
and they were prepared as follows.
The pcDNA3.1Myc-PHOX2B WT and the pcDNA3.1Myc-
p.Ser207fs (c.618del) expression constructs were generated as fol-
lows: the entire cDNA region was amplified starting from the already
available pcDNA3.1TOPO-PHOX2B WT and the pcDNA3.1TOPO-
p.Ser207fs (c.618del) constructs (named pcDNA3.1TOPO-c.614_618
delC in Bachetti et al., 2005b), using a forward primer (Pr. FW: 5′-
AGCCACCTTCTCCATATCC-3′) and the following reverse primers:
Pr. REV1 (5′-CGAACATACTGCTCTTCACTAAGG-3′) for PHOX2B
WT and Pr. REV2 (5′-CAGGCGGCTTTGGCACCG-3′) for PHOX2B
p.Ser207fs; the PCR products lacking the stop codon were sub-
cloned in the pCR2.1 vector (TOPO TA Cloning; Invitrogen, Waltham,
MA, USA) and ligated in the pcDNA3.1Myc vector after EcoRI
digestion.
The pcDNA3.1 Myc-p.Ser311fs (c.930dup) plasmid was gen-
erated by means of site-specific mutagenesis starting from the
pcDNA3.1TOPO-PHOX2B WT, containing the entire 3′UTR, as
template. The entire p.Ser311fs coding region was obtained by
means of the whole amplification of the two fragments containing
the mutation, and produced using the following primers: Pr. FW
fragment 1 (5′-AGCCACCTTCTCCATATCC-3′) and Pr. REV frag-
ment 1 (5′-TACTGCTCCTTCACTAAGGCG-3′); Pr. FW fragment
2 (5′CGCCTTAGTGAAGGAGCAGTA-3′) and Pr. REV fragment 2
(5′-CGGCCCTCAATGAAAAAGCCATG-3′); after sequencing, the
PCR products underwent the process described above before being
inserted into the pcDNA3.1Myc vector.
The PHOX2B (HindIII/NcoI), DBH (−993/+1 bp) (NG_008645.1,
NM_000787.3), TLX2 (−1,885/−37 bp) (NC_000002.11,
NM_016170.4), GFAP (−2.2 kb + 9 bp) (NG_008401.1, NM_002055.4)
and RET (−5,078/+53 bp) (NG_008401.1, NM_002055.4) promoter
constructs have been previously described (Bachetti et al., 2005a.,
2010; Borghini et al., 2006; Cargnin et al., 2005; Di Lascio, Bachetti,
Saba, Ceccherini, Benfante, & Fornasari, 2013).
2.5 Fluorescencemicroscopy
HeLa cells plated on 1.7 × 1.7 cm2 glass coverslips were grown to
50% confluence and transfected with PHOX2B WT/pcDNA3.1-Myc-
His, PHOX2B-p.Ser207fs /pcDNA3.1-Myc-His, PHOX2B p.Ser311fs
/pcDNA3-HA, ormock-transfectedwith the empty vector. Immunoflu-
orescence was performed as previously described (Cargnin et al.,
2005). The subcellular localization was analyzed on cells transfected
and fixed 48 hr after transfection. The Myc-tagged PHOX2B pro-
teins were detected by means of mouse anti-Myc antibody (1:150;
Sigma-Aldrich, St. Louis, MO, USA, #) and the secondary DyLight
549-conjugated goat anti-mouse antibody (1:400; Jackson ImmunoRe-
searchWest Grove, PA, USA, #115-505-146). The nuclei were stained
with DAPI, and the images were acquired by means of an LSM 510
Meta confocal microscope (Carl Zeiss, Inc., Oberkochen, Germany)
with 63× (Nikon, Tokyo, Japan) Apochromat lenses (1.5 NA).
2.6 Electrophoretic mobility shift assays
The electrophoreticmobility shift assays (EMSAs)were performed fol-
lowing a previously described protocol (Cargnin et al., 2005; Terzano,
Flora, Clementi, & Fornasari, 2000). The in vitro expression of wild-
type PHOX2B and the mutant variants was obtained using a commer-
cially available rabbit reticulocyte lysate system (TNT Quick-coupled
Transcription/Translation System; Promega,Madison,WI, USA) as pre-
viously described (Cargnin et al., 2005). The oligonucleotides bearing
the ATTA 2 and ATTA 3–4 sites of the PHOX2B promoter have been
previously reported (Cargnin et al., 2005; Di Lascio et al., 2013). All
of the oligonucleotides were purchased from Sigma—Aldrich. Mouse
anti-MYC antibody (Sigma-Aldrich, St. Louis, MO, USA; catalog no.
M5546) was used in the EMSA experiments.
3 RESULTS
3.1 Mutational screening of the PHOX2B gene in our
cohort of CCHS patients
The coding region of the PHOX2B gene has been screened in CCHS
probands and their parents, collected since 2004, using previously
reported protocols (Bachetti et al., 2011; Matera et al., 2004), and
we have identified a total of 116 cases carrying PHOX2B mutations:
the vast majority were polyAla expansions (PARMs) containing 5–13
additional residues (98 cases, 84.5%), while FS, MS, and NS mutations
(collectively NPARMs) could be detected in a minority of patients (18
cases, 15.5%; Figure 1A).
Fifty-one patients carrying PARMs have been reported previously,
22 with detailed clinical data (Matera et al., 2004; Parodi et al., 2008).
In 14 patients we detected the insertion or the deletion of one ormore
nucleotides, for a total of 11 FSmutations, as summarized in Figure 1A
and in Table 1 (in bold). Nine of these mutations have been reported
elsewhere (Bachetti & Ceccherini, 2013; Bachetti et al., 2005b;
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F IGURE 1 PHOX2B mutations identified in our CCHS panel. A: The bar chart shows the total number of cases carrying PHOX2B mutations
belonging to the different classes identified in our CCHS patients (polyAla: polyalanine expansion; FS: frameshift; MS: missense; NS: nonsense).
A description of themutations and, in parenthesis, the corresponding number of carrying samples are reported under each bar. GenBank accession
number: NM_003924.3 was used as the reference sequence for the cDNA. # indicates mutations reported here for the first time. B: Percentage of
PARM (polyalanine repeat expansion mutation) and NPARM (non polyalanine repeat expansion mutation) carriers affected with isolated or syn-
dromic congenital central hypoventilation syndrome (CCHS) and their distribution among four different categories of phenotypes: NONE (black
dots) = CCHS without any associated symptom; HSCR (dark gray) = CCHS and Hirschsprung disease; NB (white) = CCHS and neuroblastoma;
HSCR+NB (light gray)=CCHS,Hirschsprung disease and neuroblastoma.On the right, the distribution ofNPARMs according to the type ofmuta-
tion and phenotype. FS, frameshift; MS, missense; NS, nonsense
Matera et al., 2004) and two of them have also been reported by
others (Amiel et al., 2003; Berry-Kravis et al., 2006; Holzinger et al.,
2005; Sasaki et al., 2003; Trochet et al., 2005b). The c.722_759dup and
c.807_825dupmutations are reported here for the first time.
In the remaining four patients carrying NPARMs, we detected a
MS mutation in the homeodomain (HD) (c.419C>A), two in the stop
codon (c.944G>Tandc.945A>C), andoneNSmutation in the first exon
(c.18T>G), already reported elsewhere (Bachetti & Ceccherini, 2013;
Parodi et al., 2008).
In 20 patients (18 carrying PARMs and twoNPARMs), themutation
was inherited by one parent, while in the remaining patients for whom
DNA from both parents was available (76 cases) themutation arose de
novo. In six cases, for whom only one parental DNA sample was avail-
able, turned out to be negative for themutation, the de novo/inherited
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occurrence could not be verified. Overall, these data lead to a propor-
tion of sporadic cases of 74.5%.
As previously reported (Weese-Mayer et al., 2010), although less
frequent, NPARMs, and in particular FS mutations, are more severe
than PARMs and more frequently associated with syndromic forms of
CCHS (Figure 1B).
3.2 Analysis of PHOX2B FSmutations
We concentrated on FS mutations as they are more frequent than MS
or NS mutations, and are associated with a larger range of CCHS phe-
notypes. To this end, we first collected all the PHOX2B FS mutations
identified in patients with isolated or syndromic CCHS, isolated HSCR
or NB that have so far been published in the literature or, although
unpublished, come from our own CCHS patient panel.
The 31 different FS mutations are shown schematically in Supp.
Figure S1 and described in more detail in Table 1, where they are
listed on the basis of the starting point of the frame loss from 5′ to 3′
along the gene. During protein translation, these mutations can have
different consequences: (1) the phase displacement of the nucleotide
triplets can cause the creation of a premature stop codon, thus pro-
ducing a truncated protein; and (2) the correct stop codon can be sur-
passed, thus leading to an elongated protein. In this article, the correct
reading frame will be referred to as “frame 1”; the insertion of one or
more triplets +1 nucleotide and the deletion of two or more triplets
+2 nucleotides will be referred to as “frame 2”; and the insertion of
two or more triplets +2 nucleotides and the deletion of one or more
triplets +1 nucleotide will be referred to as “frame 3”. Almost all of the
FS mutations listed in Table 1 (except FS1, FS2, and FS3) arise in exon
3, and frame 2 mutations are more frequent than frame 3 mutations,
and more frequently can also cause NB in the absence of CCHS (Supp.
Figure S1 and Figure 2A).
As we were interested in the role that PHOX2B FS mutations play
in predisposing to syndromic CCHS, we concentrated on the 25 muta-
tions that have so far been identified in CCHS patients; the remaining
six (written in gray italics in Supp. Figure S1, and Figure 2A) have never
been associated with CCHS, and two have only been found in tumor
samples (Table 1).
As shown in Supp. Figure S1 and Figure 2A, (1) all of the frame 2
CCHS-related FS mutations, except FS2, produce elongated proteins
due to stop codon loss, and all of the frame 3 mutations, except FS25,
cause protein truncation due to the gaining of a premature stop codon;
(2) all of the patients with isolated CCHS present frame 3 mutations
(in red in Supp. Figure S1, and circles with black dots in Figure 2A); (3)
the vast majority of the cases of syndromic CCHS are associated with
frame 2 mutations; (4) all of the “syndromic” phenotypes associated
with frame 3 mutations include HSCR (three alone, two with NB); (5)
syndromicCCHS ismore frequently accompanied byHSCR than byNB
(Supp. Figure S2).
These observations highlight a distortion in the distribution of NB
or other TSNSamong themutations. AlthoughHSCR is associatedwith
almost all the FS mutations (alone or together with NB/TSNS, respec-
tively dark and light gray circles in Figure 2A), only two of the five
patientswith frame3mutations presentsNB (40%), whereas 10 of the
15 patients with frame 2 mutations present NB/TSNS ± HSCR (66.6
%), thus suggesting that the predisposition to developing NB/TSNS is
greater in the case of frame 2mutations.
3.3 Consequences of FS start site in relation to the
polyAla region
FS mutations of the PHOX2B gene may occur upstream, downstream,
or inside the polyAla region (Supp. Figure S3), and their effect on the
final gene product depends on both their position and the class of
frame shift (Supp. Figures S4 and S5).
In relation to their position, frame 2 mutations are scattered
throughout thewhole gene: sixmutations occur upstream, three inside
and six downstream the polyAla region; conversely, almost all frame 3
mutations occur upstreamof the polyAla stretch,with only two located
within the repeat (Supp. Figure S4). The proportion of frame 2 muta-
tions inside and downstream of the polyAla region associated with
bothHSCRandNB/TSNS is slightly higher than that of upstreammuta-
tions (six out of nine=66%vs. three out of six=50%) (Supp. Figure S5).
Moreover, the most severe frame 3 mutation (associated with HSCR
(TCA)+NB) is an insertion of 17 nt (FS22) affecting the polyAla region
(Supp. Figure S4).
Interestingly, mutations affecting the polyAla region involve the
insertions/deletions of amuch larger number of nucleotides than those
arising outside the repeat and, unlike the triplet duplications leading to
polyAla expansions which occur throughout the polyAla region (Mat-
era et al., 2004), four out of the six FS mutations occurred inside the
polyAla region start from the first codon, thus disrupting the entire
stretch of 20Ala residues (FS 20, 21, 23, and 24). In the presence of
frame 2 mutations upstream of and inside the polyAla region, the 20
alanine residues domain is enriched in glycine (Gly) and serine (Ser)
residues, and an additional seven alanine sequence is produced within
the translated portion of the 3′UTR, whereas in the presence of frame
3 mutations in the same positions, the 20 alanine residues stretch is
enriched in arginine (Arg) and Gln residues (Supp. Figure S3).
3.4 Inheritance of PHOX2B FSmutations
As shown in Figure 2B and Table 1, the possible inheritance of the
PHOX2B FS mutations that cause CCHS ± ASN symptoms could be
assessed only for 21 mutations: three mutations (FS 10, 21, and 24),
accounting for 15 patients, were reported to be both de novo and
inherited; seven of the remaining eighteen were de novo, and eleven
were inherited from one parent. The frame 2: frame 3 ratio is 5:2
among the de novomutations, and 5:6 among the inheritedmutations;
further the percentage of frame 3 inherited mutations is higher than
that of frame 2 (six out of a total of eight frame 3 mutations = 75% vs.
five out of a total of ten frame 2 mutations = 50%), which is in line
with the view that frame 3 mutations are less severe and may be
incompletely penetrant.
With respect to their position, we observed that three of the 10
mutations upstream of the polyAla stretch were de novo and seven
were inherited; among the three mutations inside the polyAla region,
one was de novo and two, identified in four probands, were inherited
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F IGURE 2 ANS symptoms in CCHS patients carrying FS PHOX2Bmutations. A: Distribution of ANS symptoms in syndromic CCHS by FS muta-
tion. The hierarchical diagram shows the number of FSmutations (in the circles) divided on the basis of the class of patients (thosewith andwithout
CCHS), clinical manifestation (isolated or syndromic), and the type of frame (2 or 3). Mutations associated with isolated CCHS (circles with black
dots), without any other symptom, are indicated with NONE. The ANS dysfunctions associated with CCHS are indicated for each patient class:
HSCR (dark gray)=CCHS andHirschsprung disease; NB (white)=CCHS and neuroblastoma; HSCR+NB/TSNS (light gray)=CCHS, Hirschsprung
disease and neuroblastoma/tumors of the sympathetic nervous system. B: Distribution of ANS symptoms based on the inheritance of FS muta-
tions. Only those 21 FS mutations for which information on inheritance was available are considered. The hierarchical diagram shows the number
of FSmutations (in the circles) on the basis of distribution of de novo, de novo/inherited and inheritedmutations, and the frequency of frame 2 and
frame 3 in the three groups. The position of themutations is indicated in relation to the polyAla region (upstream; inside; downstream). Among the
inherited variants, the figure shows the constitutive (C) andmosaic (M)mutations of the carrier parents. Mutations associatedwith isolated CCHS
(circles with black dots) are indicated with NONE = no associated symptoms reported (only CCHS). The associated ANS symptoms are indicated
below each circle: HSCR/HSCR (TCA)/HSCR (L) (dark gray circles) = CCHS and Hirschsprung disease/total colonic aganglionosis/long segment
HSCR; HSCR+NB/GNB (light gray)=CCHS, Hirschsprung disease and neuroblastoma/ganglioneuroblastoma)
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(in three cases from mosaic parents); interestingly, only two of the 11
patients carrying FS24, that occurs inside the polyAla, inherited the
mutation from one parent. Three of the five mutations downstream of
the polyAla region were de novo and two inherited. Thus, the majority
of inherited mutations occur upstream the polyAla stretch, in line
with the observation that mutations in the terminal part of the coding
region are likely more severe and penetrant.
Finally, the ratio between constitutive and mosaic variants among
the eleven inherited mutations was 9:2, with both mosaic variants
occurred inside the polyAla region.
3.5 PHOX2B proteins carrying c.618del
(p.Ser207fs) and c.930dup (p.Ser311fs) mutations
In order to investigate themolecularmechanism underlying the occur-
rence of isolated or syndromic CCHS in the presence of PHOX2B
FS mutations, we characterized the c.618del (p.Ser207Alafs*102)
and c.930dup (p.Ser311Glufs*49fs) variants, which have very differ-
ent characteristics (Supp. Table S2). To simplify, according to the
HGVS nomenclature of variants, the full name of mutant proteins
derived from c.618del and c.930dup hereon has been shortened from
p.Ser207Alafs*102 to p.Ser207fs and p.Ser311Glufs*49 to p.Ser311fs,
respectively.
The c.618del mutation previously reported by Matera et al. (2004)
was inherited from the asymptomatic mother and is associated with a
mild respiratory phenotype,whereas the clinical phenotype associated
with the c.930dupmutation reportedbyBachetti et al. (2005b), is quite
severe, with apnea during sleep, total colon aganglionosis (TCA), and
early onset NB.
The c.618del and c.930dup mutations lead to different aberrant C-
terminal regions of the protein: the first causes a shift of the transla-
tional frame from amino acid 207 and leads to a truncated protein of
307 amino acids (frame 3, Figure 3A); the second affects the distal part
of the protein and the induced shift leads to an elongated protein of
358 amino acids (frame 2, Figure 3A).
Interestingly, the elongated protein differs from the wild-type
protein in terms of the loss of the last four amino acids and the
novel 44 amino acid C-terminal that includes an additional polyAla
stretch of seven residues from residue 320 to residue 326 (boxed in
Figure 3A).
The secondary structure of the PHOX2B protein, which was pre-
dicted using the PSIRED server (https://bioinf.cs.ucl.ac.uk/psipred/)
(Buchan et al., 2013; Jones, 1999), indicates the presence of 𝛼-helices
in the HD as previously reported for other HD proteins (data not
shown), and in the C-terminal region: one long helix in the 20 polyAla
stretch and one shorter helix in the terminal part of the protein from
residue 304 to residue 310 (Figure 3B). In the p.Ser311fs (c.930dup)
mutant the C-terminal helix is substituted by two close helices sepa-
rated by a short protein sequence in a random coil conformation, the
second ofwhich corresponds to the additional polyAla stretch of seven
residues (residues 306–316 and 320–326; Figure 3B). The p.Ser311fs
mutant is also characterizedby thepresenceof an additional helix from
residues 344 to 355, corresponding to the terminal part of the novel
elongated tract.
The p.Ser207fs (c.618del) mutant is characterized by the replace-
ment of the polyAla tract by an Arg/Gln-rich stretch generating two 𝛼-
helices insteadof one,which are separatedby a short protein sequence
in a random coil conformation (residues 239–244 and 253–266;
Figure 3B).
3.6 Effect of p.Ser207fs and p.Ser311fs mutant
proteins on PHOX2B expression
An auto-regulatory mechanism based on PHOX2B binding its own
promoter allows PHOX2B to control and sustain its own expression
(Cargnin et al., 2005). As most FS mutations show a decrease in trans-
activating regulatory regions of different PHOX2B target genes (i.e.,
DBH, PHOX2A, and TLX2) (Bachetti et al., 2005b; Borghini et al., 2006;
Nagashimada et al., 2012; Trochet et al., 2005a, 2009), we investi-
gated the ability of the p.Ser207fs and p.Ser311fs mutants to regulate
PHOX2B expression in terms of the transactivation of thePHOX2Bpro-
moter.
To this end, we co-transfected HeLa cells with the PHOX2B pro-
moter reporter construct and each of the twoPHOX2B expression con-
structs. As shown in Figure 4A, the forced over-expression of wild-
type PHOX2B induced a fivefold increase in reporter gene expres-
sion in comparisonwith the empty pcDNA3.1Myc-His vector, whereas
the two mutants showed significantly less activity, with that of the
p.Ser311fs mutant being almost reduced to basal level (given the
unspecific transactivation shownwhen co-transfectingwith the empty
phRG-B reporter vector).
In order to test the ability of the PHOX2B mutants to bind the
PHOX2B promoter, we used EMSAs and radiolabelled oligonucleotides
containing the ATTA 2 and ATTA 3–4 sites, which have the highest
affinity for the protein expressed in vitro (Cargnin et al., 2005). Incuba-
tion of the wild-type protein with each radio-labeled oligonucleotide
caused the appearance of specific retarded bands (complex I in Fig-
ure 4B, and I and II in Figure 4C) that could be competed with a molar
excess of cold oligonucleotide and were supershifted by the anti-Myc
antibody (Figure 4B and C, lanes 1–3).
The two frameshift mutations almost completely abolished DNA
binding, an effect that was stronger than that shown by the longest
expansion (p.Ala241[33]; +13 alanine) (Figure 4B and C, lanes 4–
12). As in the case of the +13 alanine mutant, the presence of the
p.Ser311fs mutant led to the appearance of a band at the top of the
gel, corresponding to thewell (Figure 4B andC, lanes 10–12), thus con-
firming that this protein has a tendency to oligomerize. Incubation of
the p.Ser207fsmutant proteinwith each radio-labeled oligonucleotide
caused the appearance of a very weak and faster retarded band (com-
plex II, Figure 4B, lane 7, and complex III, Figure 4C, lane 7) that could
be competed with a molar excess of cold oligonucleotide, but was not
super-shifted by the anti-Myc antibody, thus suggesting abnormal pro-
tein conformation.
Gel filtration analyses have shown that frameshift mutants (regard-
less of the frame) have a strong tendency to oligomerize in vitro; how-
ever, cytoplasmic aggregation has not been reported for the frameshift
mutants, including the p.Ser207fs and p.Ser311fs mutants (Bachetti
et al., 2005b; Raabe et al., 2008; Reiff, Tsarovina, Majdazari, Schmidt,
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F IGURE 3 Sequences and predicted secondary structures of PHOX2BWT and PHOX2B p.Ser207fs and p.Ser311fs mutants. The full name of
mutant proteins derived from c.618del (p.Ser207Alafs*102) and c.930dup (p.Ser311Glufs*49) has been shortened in p.Ser207fs and p.Ser311fs.
A: Alignment of the amino acid sequences of PHOX2B wild-type protein and the PHOX2B proteins encoded by the c. 618del (p.Ser207fs) and
c.930dup (p.Ser311fs) mutant genes. The regions of the three proteins that show homology are in black, and the regions of homology between the
PHOX2B wild-type and p.Ser311fs mutated proteins are in gray. The alanine-rich regions are boxed. B: The secondary structures of the PHOX2B
wild-type andmutated isoformswere predicted using the PSIPRED server. Only the tail sequenceswere used as identity is maintained up to amino
acid 206. The program predicts the possibility of a helix (box) or a coil (straight line) for the target amino acid sequences. GenBank accession num-
bers: NM_003924.3 was used as the reference sequence for the cDNA andNP_003915.2 for the protein
del Pino, & Rohrer, 2010; Trochet et al., 2005a). Interestingly, we
have previously found that p.Ser207fs mutants mainly accumulate in
nuclear sub-compartments resembling the nucleoli (Bachetti et al.,
2005b), and that intra-nuclear aggregations due to polyAla expan-
sions inversely correlate with the amount of transfected DNA (Di
Lascio et al., 2013; Di Zanni et al., 2012). In order to avoid the
effect of exogenous DNA, we analyzed the sub-cellular localization
of p.Ser207fs and p.Ser311fs upon transfection of the same amount
of constructs as that used for the transactivation assays described
above, which is much lower than that used in earlier studies. We con-
firmed that both mutants localized to the nucleus in all transfected
cells, where the p.Ser207fs protein showed partial accumulation to
the characteristic ring of DAPI-positive chromatin surrounding the
nucleoli (Figure 4D, panels d–f), whereas, interestingly, the p.Ser311fs-
expressing cells showed the formationof nuclear inclusions (Figure4D,
panels g–i).
3.7 Effects of PHOX2B p.Ser207fs and p.Ser311fs
mutant proteins on the expression of CCHS-related
genes
To investigate the molecular mechanisms underlying the occurrence
of HSCR and NB in CCHS patients, we tested the effects of the two
FS mutations on the promoter regions of genes that play a role in
the clinical manifestations of these diseases. In particular, in order to
account for the development of HSCR, we investigated their effect on
the promoter of the RET gene, which has previously been identified
as a PHOX2B target gene (Bachetti et al., 2005a) and whose loss-of-
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F IGURE 4 Functional effects of PHOX2B wild-type and mutant proteins on the PHOX2B promoter. The full name of mutant proteins derived
from c.618del (p.Ser207Alafs*102) and c.930dup (p.Ser311Glufs*49) has been shortened in p.Ser207fs and p.Ser311fs. A: Luciferase assay. The
bars indicate the transcriptional activity of the PHOX2B promoter reporter construct upon co-transfection in HeLa cells with PHOX2B expression
vectors containing the cDNAofwild-type protein or carrying the frameshift mutations (black bars). pcDNA3.1Myc-His indicates the empty vector
used as a negative control. The white bars show the transcriptional activity of the corresponding empty reporter construct (phRG-B) upon co-
transfectionwith thePHOX2Bexpression vectors. The results are themean values± SD (error bars) of the transcriptional activity of the constructs
in at least three experiments performed in triplicate (= 3), and are expressed as percentages of the activity of the reporter plasmid co-transfected
with theWTprotein (=1). ***Significant differences between the luciferase activity of the reporter plasmid co-transfectedwithPHOX2Bwild type-
encoding vector and the tested mutants (ANOVA, Tukey's test, P< 0.001). B and C: Gel shift assays using oligonucleotide probes corresponding to
the regions of thePHOX2Bpromoter containingATTAcoremotifs that have been shown to bindPHOX2B. The labeled probeswere incubatedwith
in vitro expressed Myc-tagged PHOX2B wild-type protein (lanes 1–3), or mutated PHOX2B proteins (lanes 4–12). The in vitro translated pcDNA
3.1Myc-His empty vectorwasused as a control to excludenon-specific interactions (lanes13). The competitionswere carriedout by adding amolar
excess of unlabeledoligonucleotide (lanes 2, 5, 8, and11). Supershift experimentswere performedbypre-incubating the in vitro expressedproteins
with anti-Myc antibody (lanes 3, 6, 9, and 12). The roman numbers on the left indicate the specific retarded complexes obtained using the in vitro
expressed PHOX2B proteins; the asterisks indicate the supershifted complexes containing PHOX2B. The free probes are visible at the bottom of
the gels.D: Representative immunofluorescence images of the localization of the PHOX2B wild-type and the mutated p.Ser207fs and p.Ser311fs
proteins. HeLa cells were transfected with theMyc-tagged proteins and analyzed 48 hr after transfection by means of immunofluorescence using
anti-Myc antibody (b, e, and h); the nuclei were visualized using DAPI (a, d, and g), andmergedwith the proteins detected by the anti-Myc antibody
(c, f, and i). Scale bars: 10 𝜇m
function (LOF) mutations are responsible for 15%–50% of the cases of
HSCR cases (most of the others are caused by gene downregulation)
(Griseri, Bachetti, Puppo, Lantieri, Ravazzolo, Devoto, & Ceccherini,
2005).
As shown in Figure 5A, the transfection of SK-N-BE cells with
the two PHOX2B constructs and the RET promoter reporter plasmid
showed that the p.Ser207fs mutant (which is not known to be asso-
ciated with HSCR) transactivated the RET promoter to an extent that
was comparable with that of the wild-type protein, whereas the activ-
ity of the p.Ser311fs mutant was significantly less.
It has previously been reported that, in patients with NB, PHOX2B
FS mutations cause developing cells to switch incorrectly toward
neuron differentiation, thus leaving them in undefined state than
can be detected by double staining for markers of neurons and glia
(Nagashimada et al., 2012). We therefore tested the effect of the
PHOX2B mutants on a reporter construct containing the entire pro-
moter region of the glial acidic fibrillary protein (GFAP) gene, a known
astrocyte marker. As shown in Figure 5B, neither the wild-type pro-
tein nor the p.Ser207fs mutant (which is known not to be associated
with NBs) transactivated the GFAP promoter, whereas the p.Ser311fs
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F IGURE 5 Transactivation of the RET andGFAP promoters by PHOX2Bwild-type andmutant proteins. The full name ofmutant proteins derived
from c.618del (p.Ser207Alafs*102) and c.930dup (p.Ser311Glufs*49) has been shortened in p.Ser207fs and p.Ser311fs. The bars indicate the tran-
scriptional activity of the RET promoter reporter construct upon co-transfection with PHOX2B expression vectors containing the cDNA of WT
protein (white bars) or mutated proteins (black bars) in SK-N-BE cells (A) and the GFAP promoter reporter construct upon co-transfection with
PHOX2B expression vectors containing the cDNA of WT protein (white bars) or mutated proteins (black bars) in U251-MG cells (B). pcDNA3.1
Myc-His indicates the empty vector used as a negative control (hatched bars). The results are the mean values ± SD (error bars) of the transcrip-
tional activity of the constructs in at least three experiments performed in triplicate, and are expressed as fold induction over the activity of the
reporter plasmid co-transfected with the empty vector. *Significant differences in comparison with the activity of the wild-type protein (Student t
test, P< 0.05)
mutant, which has been detected in a patient with NB, significantly
increasedGFAP transcription.
3.8 Dominant-negative effects of PHOX2B
p.Ser207fs and p.Ser311fs mutant proteins on the
transcriptional activity ofWTPHOX2B
As it has previously been reported that PHOX2B proteins with ala-
nine expansions and FS mutations have dominant-negative effects (Di
Lascio et al., 2013; Nagashimada et al., 2012; Parodi et al., 2012; Pei,
Luther, Wang, Paw, Stewart, & George, 2013; Reiff et al., 2010; Tro-
chet et al., 2009), we tested whether the PHOX2B p.Ser207fs and
p.Ser311fs mutant proteins interfered with the activity of wild-type
protein when co-expressed in equimolar amounts.
The co-transfection experiments were performed using the regu-
latory regions of four PHOX2B target genes: PHOX2B (Cargnin et al.,
2005), DBH (Adachi et al., 2000; Yang, Kim, Seo, Kim, Brunet, & Kim,
1998), TLX2 (Borghini et al., 2006), and RET (Bachetti et al., 2005a). As
already known (Bachetti et al., 2005b; Borghini et al., 2006; Di Lascio
et al., 2013), the transfection of wild-type PHOX2B significantly trans-
activated all of these reporters (Figure 6, white bars). Moreover, the
transcriptional activity of the p.Ser311fs mutant on the PHOX2B and
RET reporter genes was significantly less, and almost completely abol-
ished to basal level when co-transfected with TLX2 and DBH reporter
genes (Figure 6, black bars). With the exception of the PHOX2B gene
reporter, the levels of transactivation were significantly higher with
p.Ser207fs mutant, whose transactivation activity was comparable
with that of the wild-type protein in the case of the TLX2 and RET pro-
moters (Figure 6, black bars).
When we co-transfected both wild-type and mutant proteins at a
ratio of 1:1, the reporter activity of the PHOX2B, DBH, and TLX2 genes
induced by the wild-type protein was significantly reduced in the pres-
ence of either mutant (Figure 6, cross-hatched bars), the inhibitory
effect of which was much greater in the case of p.Ser311fs mutant. On
the contrary, when both FS mutants were tested on the RET reporter,
transcriptional activity significantly increased (Figure 6, cross-hatched
bars) and, remarkably, was comparable with the reporter activity
obtained when testing a double amount of wild-type PHOX2B, thus
suggesting that the p.Ser311fs mutant, whose ability to transactivate
the RET promoter was reduced, does not interfere with the transacti-
vation capacity of wild-type PHOX2B.
Taken together, our in vitro functional studies show that FS muta-
tions have effects depending on the target promoter. When cluster-
ing the promoters in gene categories (±HSCR and NB), and consider-
ing transcription down-regulation as a LOF effect and acquired upreg-
ulation as a gain-of-function (GOF) effect, the c.618del (p.Ser207fs)
mutation has a slight LOF effect only on the promoters of the genes
predisposing to CCHS, whereas the c.930dup (p.Ser311fs) mutation
has a more marked LOF effect on all of the promoters other than the
GFAP promoter, on which it has GOF effects (Figure 7).
4 DISCUSSION
This article provides a detailed description of all of the FS muta-
tions identified so far in CCHS patients and a classification of the
associated symptoms in terms of neurocristopathies (mainly HSCR
and NB); it also describes the results of functional studies aimed at
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F IGURE 6 Transcriptional effects of PHOX2B wild-type plus mutant proteins on the activity of PHOX2B, DBH, TLX2, RET target promoters. The
full name of mutant proteins derived from c.618del (p.Ser207Alafs*102) and c.930dup (p.Ser311Glufs*49) has been shortened in p.Ser207fs and
p.Ser311fs. A–D: Luciferase assays. The bars indicate the transcriptional activity of the PHOX2B (A), DBH (B), TLX2 (C), and RET (D) promoter
reporter constructs upon co-transfection with PHOX2B expression vectors containing the cDNAs of WT protein (white bars), mutated proteins
(black bars) or a combination of equimolar amounts (1:1 ratio) of PHOX2Bwild-type andmutated protein expression vectors (cross-hatched bars)
in HeLa cells and (for the RET promoter) SK-N-BE cells. pcDNA3.1 Myc-His indicates the empty vector used as a negative control (hatched bars).
The results are the mean values ± SD (error bars) of the transcriptional activity of the constructs in at least three experiments performed in trip-
licate, and are expressed as percentages of the activity of the reporter plasmid co-transfected with the wild-type protein under hemizygous con-
ditions (= 100). Significant differences between the activity of the wild-type protein and the mutants (ANOVA, Tukey's test: *P < 0.05, **P < 0.01,
***P < 0.001); significant differences between the activity of the wild-type protein when co-transfected with each mutant (ANOVA, Tukey's test:
#P< 0.05, ##P< 0.01)
investigating the molecular mechanisms underlying isolated and syn-
dromic CCHS.
The graphic representation of the mutant proteins offers informa-
tion that is useful formolecular diagnosis and genetic counseling as the
position of the mutation, and therefore the start of the translational
frame, is critical for predicting its structural and clinical consequences.
Frame 2 mutations are more frequently associated with syndromic
CCHS than frame 3mutations, andmutations starting upstream of the
polyAla region are generally less severe than those occurring within
and downstream of the repeated stretch. It is possible to postulate
that polyAla region plays a role in FS mutation-mediated pathogene-
sis. Although the long PHOX2B insertions/deletions span the polyAla
stretch starting from the first triplet and lead to the aberrant trans-
lation of the polyAla region, it is not clear whether an intact polyAla
stretchor its disruption ismoredeleterious.Mutations in theproximity
of the 3′ end of the coding region (c.866dup, c.930dup, c.931_935del,
c.936dup) and characterized by an intact polyAla region are very
severe. This is somehow unexpected as these distal mutations share
the same aberrant C-terminal sequence with other frame 2 mutations
that are associated with HSCR alone (c.608dup, c.617_618insT, and
c.693_700del) and, except for a few amino acids, the wild-type protein
sequence is completely preserved. This observation does not support
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F IGURE 7 Summary of the effects of PHOX2B on target gene promoters. The full name of mutant proteins derived from c.618del
(p.Ser207Alafs*102) and c.930dup (p.Ser311Glufs*49) has been shortened in p.Ser207fs and p.Ser311fs. The summary of the effects of PHOX2B
WT and the two mutants on PHOX2B, DBH, TLX2, RET, and GFAP promoters is shown. In the two columns on left, the constructs are indi-
cated with the corresponding associated clinical phenotype: CCHS = congenital central hypoventilation syndrome; NB = neuroblastoma;
HSCR = Hirschsprung disease. A: Effect on transactivation activity. The degree of transactivation is indicated by the number of “+” signs; a “–“
sign indicates no transactivation.B: The presence or absence of a dominant negative effect is respectively indicated by “yes” and “no”. n.a.: untested
effect because of acquired function instead of loss of function. C: The effects of the c.618del (p.Ser207fs) and c.930dup (p.Ser311fs) mutants are
represented for each promoter as loss-of-function (LOF) or gain-of-function (GOF) at the bottom of the table. A “-” sign indicates no effect
the hypothesis that the association of frame 2mutationswith a predis-
position to CCHS-related ANS disorders is solely due to the aberrant
amino acid tail.
Another factor that could play a role is the generation of novel
domains enriched in particular amino acids. When frame 3 mutations
begin upstreamof the polyAla stretch, the frame change leads to a pro-
tein sequence rich in basic aminoacids (Gln–Arg),whichhavebeen sug-
gested to be the cause of the localization of the p.Ser207fs protein
in the nucleolar compartment (Bachetti et al., 2005b). Arg methyla-
tion is a frequent post-translational modification involved in a number
of cell processes (Blanc & Richard, 2017), and may confer anomalous
properties to an already mutant PHOX2B protein. The Gly–Ser-rich
domain, generated in the polyAla regionwhen frame2mutations occur
upstream of or at the beginning of the polyAla region, could be a target
of phosphorylation or a spacer between protein domains, making the
protein structure more relaxed (Reddy Chichili, Kumar, & Sivaraman,
2013). Finally, the 7-residue polyAla region aberrantly translated from
the 3′UTR when frame 2 mutations occur may take on a pathogenic
role as a spacer between domains or in protein–protein interactions.
In order to investigate further the molecular basis of the differ-
ences in the pathogenicity of frame 2 and frame 3 mutations, we
tested the functional effects of the expression of two mutants repre-
sentative of different CCHS-associated clinical phenotypes on a num-
ber of PHOX2B target genes. It is worth noting that both of the
mutants under analysis showed severe defects in DNA binding but
retained some transcriptional activity. In the case of p.Ser207fs, this is
consistent with our recent reports concerning the role of the C-
terminal domain as an important modulator of HD-mediated DNA-
binding (Di Lascio et al., 2016), but DNA binding defects are unex-
pected in the case of the c.930dupmutant as it has been reported that
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proteins carrying mutations in the same region (i.e. c.931_935del and
c.936dup) retain some ability to bind DNA, albeit partially misfolded
(Trochet et al., 2005a).Ourdata indicate that changes in theC-terminal
domain affectHD folding and/or functions, but do not completely abol-
ish the transactivation capacity of themutants, which leads us to spec-
ulate that these aberrant sequences can still recruit co-transactivators.
This is reasonable in the case of the RET promoter whose expression is
likely regulated by PHOX2B through an indirect mechanism (Bachetti
et al., 2005a), but it is intriguing in the case of the TLX2 and GFAP pro-
moters. GFAP promoter transactivation by p.Ser311fs mutant may be
due to a novel direct interaction or, alternatively, the new C-terminal
regionmay recruit novel co-transactivators that do not normally inter-
act with the wild-type protein. In any case, the induction of GFAP
expression reflects the occurrence of GOF effects of the c.930dup
mutation.
In vivo studies have provided evidence of functional differences
between PARM and NPARM mutations. Mouse models of CCHS
expressing PARM or NPARM mutations of Phox2b show respiratory
distress with the selective loss of the retro-trapezoid nucleus and
an abnormal development of locus coeruleus, (Dubreuil et al., 2008;
Nagashimada et al., 2012; Nobuta et al., 2015). In addition, mice with
frame 2 FS mutations show defects in a much broader range of neu-
ronal populations, including the autonomic ganglia (Nagashimadaet al.,
2012). This can be at least partially explained by differences in the
transcriptional properties of the PHOX2B mutants as PARM mutants
showed no dominant-negative effects on the activity of wild-type pro-
tein (Di Lascio et al., 2013), unlike the twoNPARMmutants analyzed in
this study.
In our study, both mutants showed a reduced ability to induce
the correct transactivation of the PHOX2B promoter, and had simi-
lar inhibitory effects on the wild-type protein. Given the milder clin-
ical phenotype shown by the patient carrying the c.618del mutation
in comparison with that associated with the c.930dup mutant, its neg-
ative effects are somehow unexpected. Furthermore, its dominant-
negative effectsweremilder than those of the c.930dupmutant, which
suggests that other mechanisms may underlie the clinical manifesta-
tions.
Results obtained in vivo argue against the idea that CCHS is due
to a pure LOF mechanism (Dubreuil et al., 2008; Durand et al., 2005;
Ramanantsoa et al., 2006, 2011) and suggest that the ANS symptoms
of the enteric andNBphenotypes seem to be associatedwith PHOX2B
gene dosage (Goridis, Dubreuil, Thoby-Brisson, Fortin, &Brunet, 2010;
Trochet et al., 2009). Our previous findings indicate that proteins car-
rying the shortest alanine expansions do not apparently alter PHOX2B
auto-regulation (Di Lascio et al., 2013) and, it can be hypothesized
that, when the auto-regulatory loop is only marginally involved (as
in the case of the shortest polyAla expansions), the phenotype is less
severe and limited to respiratory function. On the contrary, when
the auto-regulatory loop becomes affected, PHOX2B expression can
drop below a critical threshold, thus increasing the severity of the
respiratory phenotype and the appearance ofmore general autonomic
deregulation. A dose reduction to <50% (sub-haploinsufficiency)
may be required as mice that are haploinsufficient for Phox2b do not
develop tumors. As human phenotypes varying from mild to severe
have been associated with deletions in the PHOX2B gene, including
one case with CCHS and a neural crest tumor (Jennings et al., 2012),
it is necessary to consider alternative mechanism(s) that may induce a
predisposition to NB.
PHOX2B haploinsufficiency also plays a role in HSCR by acting
as a predisposing factor for intestinal developmental and functional
defects (Fernández et al., 2013). We have also recently reported that
polyAla contractionsmay predispose toHSCR by down-regulating RET
transcription, albeit to a lesser extent than polyAla expansions (Di
Zanni et al., 2017). In line with the marked correlation between frame
2 mutations and syndromic forms of CCHS, our functional data show
that the transactivation of genes involved in enteric nervous system
development (TLX2 and RET) is much more impaired by frame 2 than
by frame 3 mutations. Furthermore, the p.Ser311fs mutant gained
the ability to transactivate the promoter of the GFAP gene, a marker
of glial cells, which is in line with in vivo evidence that two frame 2
NPARMs induce the differentiation of progenitors to glial cells fate
(Nagashimada et al., 2012).
As previously reported in the case of PARM mutations, our data
indicate that the dominant-negative effects of PHOX2B NPARM
proteins are promoter specific and probably due to aberrant protein-
protein interactions. Further characterization and the identification of
novel molecular interactions and targets are required to clarify further
the relationship between NPARM mutants and the molecular patho-
genesis of the CCHS-HSCR-NB association. In particular, we suggest
that the risk of finding an aganglionic colon in patients with frame 3
mutations depends on the specific mutation itself as only 50% of such
mutations cause HSCR (the others are neutral and only cause CCHS).
Moreover, HSCR is congenital and its diagnosis is certain, whereas
the risk of developing NB in the first years of life is more difficult to
estimate: it is therefore crucial to follow up CCHS patients carefully in
order to be able to define genotype–phenotype correlations in more
details.
In conclusion, the findings of this study show that NPARM mutant
proteins have a combination of dominant-negative, LOF and GOF
effects that depend on the analyzed promoter. Our data indicate that
DBH, TLX2, RET, and PHOX2B are target genes susceptible to the
reduced activity of NPARM proteins, and that the GFAP gene is a new
aberrant molecular target. Finally, they show that some of the func-
tional differences among the mutations belonging to different frame
subgroups are the underlying cause of the ANS disorders associated
with CCHS.
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